Nyowani Cleveland Clinic tsvagiridzo inoratidza kekutanga kuti FDA-inogamuchirwa ibrutinib (ibrutinib) ye lymphoma uye leukemia inogona zvakare kubatsira kurapa akajairika uye anouraya matumbo ehuropi, uye rinogona rimwe zuva kushandiswa kune varwere vane glioblastoma Uye kuvandudza mwero wekupona.
Sekureva kwemushumo weAmerican Brain Tumor Association, chiyero chekupona kweglioblastoma chakaderera, uye kurarama kwepakati kwevarwere vanowana kurapwa kwakajairwa kuri pasi pemwedzi gumi nemishanu. Glioblastoma ndiyo inonyanya kuuraya bundu repfungwa uye inoshingirira pakurapa kwazvino. Pave kudiwa nechimbichimbi kupa varwere ava mishonga mitsva nekukasika.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumor in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
